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Introduction {#sec005}
============

Several previous studies have shown a significantly increased risk of cardiovascular diseases in COPD and clinicians have long recognized that cardiovascular diseases are the major contributor to morbidity and mortality in patients with COPD \[[@pone.0224999.ref001],[@pone.0224999.ref002]\].

Other respiratory diseases have been associated with cardiovascular diseases. Large population studies showed that patients with chronic bronchitis (CB), a respiratory condition associated with a decline in lung function \[[@pone.0224999.ref003]\], have increased respiratory, cardiovascular and all-cause mortality \[[@pone.0224999.ref004]--[@pone.0224999.ref007]\].

Data on the association between asthma and cardiovascular diseases are conflicting \[[@pone.0224999.ref008]--[@pone.0224999.ref014]\], and few studies have addressed the relationship between rhinitis and cardiovascular diseases \[[@pone.0224999.ref015]--[@pone.0224999.ref017]\].

Previous research on the intriguing coexistence of respiratory and cardiovascular diseases generally focused on a single respiratory disorder, and few studies investigated the cardiovascular risk factors associated with airway illnesses. With this in mind, we aimed to investigate the association of cardiovascular diseases and cardiovascular risk factors with CB, asthma and rhinitis, by analysing data collected in the population-based Gene Environment Interactions in Respiratory Diseases (GEIRD) study.

Methods {#sec006}
=======

Study design and selection of the cohort {#sec007}
----------------------------------------

GEIRD is a two-stage multicentre, multicase--control study carried out in Italy ([www.geird.org](http://www.geird.org/)) \[[@pone.0224999.ref018]\]. In the first stage, new random samples of adults (GEIRD 20--64 years) and elderly subjects (GEIRD 65--85 years), male/female = 1/1, or pre-existing randomly sampled cohorts from the general population (ISAYA, ECRHS Italy and ECRHS III) were surveyed for respiratory symptoms between 2006 and 2010 using a postal questionnaire, as reported in [Table 1](#pone.0224999.t001){ref-type="table"} and described elsewhere \[[@pone.0224999.ref019]\]. Overall, 14,513 subjects from the centres of Verona, Pavia, Torino, Ancona, Sassari answered the questionnaire (response rate: 59%). All the subjects who reported symptoms suggestive of asthma or chronic bronchitis, a random sample (30%) of the subjects who reported rhinitis or hay fever and a random sample (40%) of the subjects who did not report respiratory symptoms, diagnoses or hospitalizations were invited to clinics. Additionally, a sample of 439 subjects from Palermo was invited. Overall, 7,025 subjects were invited to GEIRD stage-2 \[[@pone.0224999.ref020]\]. Between 2007 and 2015, the participants in GEIRD stage-2 were 2,911 subjects (participation rate: 41%). In all centres, clinical examinations were carried out following standardised protocols. Ethical approval was obtained from the following ethics committees: Verona, Comitato Etico per la Sperimentazione dell'Azienda Ospedaliera Istituti Ospitalieri di Verona; Turin, Comitato Etico dell'Azienda Sanitaria Locale TO/2 di Torino; Pavia, Comitato di Bioetica della Fondazione IRCCS Policlinico San Matteo di Pavia; Ancona, Comitato Etico dell'Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona; Sassari, Comitato di Bioetica dell'Azienda Sanitaria Locale di Sassari; Palermo, Comitato Etico dell'Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello. Written consent was obtained from each participant.

10.1371/journal.pone.0224999.t001

###### Study population by centre and cohort.

![](pone.0224999.t001){#pone.0224999.t001g}

  Center         Cohort         Invited to stage 2   Participating in stage 2   Included in the analysis   Females (%)   Age, years
  -------------- -------------- -------------------- -------------------------- -------------------------- ------------- -----------------
  Verona         ECRHS III      185                  98                         95                         47.4          54.2 ± 7.6
  GEIRD 20--64   2,961          1,329                1,165                      52.2                       44.5 ± 10.2   
  ISAYA                                                                                                                  
  ECRHS Italy                                                                                                            
  GEIRD 65--84   591            132                  97                         34.0                       71.8 ± 2.8    
  Turin          ECRHS III      178                  76                         69                         55.1          53.9 ± 6.3
  GEIRD 20--64   589            359                  282                        52.1                       46.8 ± 10.3   
  Pavia          ECRHS III      186                  95                         86                         53.5          57.2 ± 6.7
  GEIRD 20--64   489            241                  204                        62.3                       50.9 ± 11.0   
  Ancona         GEIRD 20--44   575                  99                         91                         53.8          42.3 ± 5.3
  Sassari        GEIRD 65--84   439                  189                        122                        32.0          74.2 ± 4.3
  ISAYA          393            230                  207                        49.3                       45.0 ± 6.9    
  Palermo        GEIRD 65--84   439                  63                         45                         33.3          75.1 ± 4.7
  **Overall**    ** **          **7,025**            **2,911**                  **2,463**                  **50.7**      **49.5 ± 12.8**

ECRHS, European Community Respiratory Health Survey; GEIRD, Gene Environment Interactions in Respiratory Diseases; ISAYA, Italian Study on Asthma in Young Adults.

Clinical measurements {#sec008}
---------------------

Forced expiratory volume in 1 s (FEV~1~) and forced vital capacity (FVC) were measured according to the American Thoracic Society reproducibility criteria \[[@pone.0224999.ref021]\]. Lung function values were expressed as a percentage of predicted values, and the lower limit of normal LLN for the FEV~1~/FVC was calculated according to Quanjer \[[@pone.0224999.ref022]\]. Spirometry was performed again 10 min after the administration of 400 μg salbutamol in subjects with FEV~1~/FVC \<70% or \<LLN. The subjects with FEV~1~/FVC ≥70% and ≥LLN underwent the methacholine challenge, according to a standardized protocol \[[@pone.0224999.ref023]\]. A subject\'s test was positive if FEV~1~ decreased by 20% at a maximum cumulative dose ≤1 mg methacholine (PD~20~ ≤1).

The subjects were skin tested for a panel of 14 aeroallergens \[[@pone.0224999.ref020]\]. A subject was considered to be atopic if positive to one or more of the tested allergens.

Identification of cases and controls in clinics {#sec009}
-----------------------------------------------

Based on the symptoms reported and the results of the clinical tests, 2,463 subjects were hierarchical classified into four groups: CB (n = 254), asthma (n = 418), rhinitis (n = 959), and controls (n = 832). The cases and control groups were defined as follows:

-   **cases of chronic bronchitis** (CB): subjects with self-reported cough and phlegm for the most of days in 3 consecutive months, during 2 years, with post-bronchodilator FEV~1~/FVC ≥70% and ≥LLN.

-   **cases of asthma**: subjects without CB who had 1) self-reported asthma, plus one among 1.1) having had an asthma attack in the last 12 months, 1.2) current use of medications for asthma; or 2) asthma-like symptoms or use of medicines for breathing problems in the last 12 months, plus one among 2.1) PD~20~ ≤1 mg, 2.2) pre-bronchodilator FEV~1~/FVC \<70% or \<LLN with a positive reversibility test (i.e. FEV~1~ improvement ≥ 12% and ≥ 200mL after 400μg of salbutamol);

-   **cases of rhinitis**: subjects without CB and asthma who had one among 1) lifetime nasal allergies, including 'hay fever'; 2) lifetime problem with sneezing, or a runny or a blocked nose (without cold/flu); 3) recurrent nasal/eye symptoms in the presence of dust, pollens or animals.

-   **controls**: subjects who were not cases and had both (i) pre-bronchodilator FEV~1~/FVC ≥70% and ≥LLN; and (ii) FEV~1~\> 80% predicted.

Sixty-eight subjects with COPD, defined as having both persistent respiratory symptoms (dyspnoea, cough, and/or sputum production) and airflow limitation (post-bronchodilator FEV~1~/FVC \<70% or \<LLN), and 380 subjects who did not correspond to any of the definitions above or with missing values on key information were excluded from the analyses.

Cardiovascular diseases {#sec010}
-----------------------

Two different self-reported doctor-diagnosed cardiovascular conditions were considered \[[@pone.0224999.ref024]\]:

1.  **heart disorders**, defined as having any among coronary heart disease ('Did a physician tell you that you suffer from: myocardial infarction, coronary thrombosis, or angina?'), heart/aortic surgery ('Have you ever undergone heart or aortic surgery?').

2.  **intermittent claudication**. A subject was considered to have intermittent claudication if he/she answered yes to the question: 'Do you get a pain or discomfort in your legs when you walk?', plus he/she reported that it usually disappeared in 10 min or less when standing still \[[@pone.0224999.ref025]\]. Intermittent claudication was adopted as proxy of peripheral arterial disease \[[@pone.0224999.ref026]\].

Covariates {#sec011}
----------

Information on the following variables was collected during the clinical interview and was taken into account for the analyses: age, gender, school education as a proxy of the socio-economic status (low if had completed full-time education before the age of 16), smoking habits (lifetime non-smoker, ex-smoker, current smoker), daily alcohol intake (lifetime non-consumer, moderate (≤15 g/day), high (\>15 g/day)), sedentary life (usually doing physical exercise less than once per month), and self-reported diabetes, hypertension or dyslipidaemia (high levels of cholesterol or triglycerides).

Statistical analysis {#sec012}
--------------------

The subjects' characteristics were summarized as percentages or means (SD). The Pearson's chi-squared test, Fisher's exact test and ANOVA were used to test differences across cases and controls (α = 0.05). The associations of cardiovascular diseases/risk factors with respiratory diseases were estimated through relative risk ratios (RRR) obtained by multinomial logistic regression models using the case/control indicator (0 = control, 1 = chronic bronchitis, 2 = asthma, 3 = rhinitis) as the dependent variable and cardiovascular diseases/risk factors as the main independent variable. Three models were fitted to the data: (i) adjusted for age and sex; (ii) further adjusted for smoking habits, alcohol consumption, body mass index (BMI, in categories \<25, 25--30 and \>30 kg/m^2^), school education and physical activity; (iii) further adjusted for the comorbidity indicators (diabetes, hypertension, dyslipidaemia). Centre was considered a clustering factor and cluster-robust standard errors were used.

Statistical analyses were performed with STATA 13.1 (Stata Corp. College Station, TX, USA).

Results {#sec013}
=======

Overall, 2,463 subjects were classified as cases or controls and included in the study. The age ranged from 21 to 86 years, and 50.7% (n = 1,249) were females ([Table 1](#pone.0224999.t001){ref-type="table"}).

As a result of our hierarchical definitions, cases of CB could also be affected by asthma (n = 115, 45.3%) as well as rhinitis (n = 205, 80.7%), and cases of asthma could also be affected by rhinitis (n = 354, 84.7%). Cases of asthma and CB had a significantly lower FEV~1~ and FEV~1~/FVC ratio than controls ([Table 2](#pone.0224999.t002){ref-type="table"}). The proportion of subjects with atopy was significantly higher among cases of CB, asthma and rhinitis (57.8, 79.0 and 62.5%, respectively) compared to the control group (26.0%).

10.1371/journal.pone.0224999.t002

###### Distribution of risk factors, clinical characteristics and lung function measurements by cases-control status.
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                                     Chronic bronchitis   Asthma        Rhinitis       Controls       p-value
  ---------------------------------- -------------------- ------------- -------------- -------------- ---------
  **Sex** (females)                  145 (57.1)           194 (46.4)    496 (51.7)     414 (49.8)     0.048
  **Age** (year)                     48.4 ± 12.8          46.4 ± 12.2   49.7 ± 13.0    51.1 ± 12.6    \<0.001
  **Low education**                  65 (25.7)            64 (15.6)     152 (16.0)     161 (19.5)     0.001
  **Smoking habits**                                                                                  \<0.001
      never smokers                  112 (44.1)           196 (46.9)    490 (51.3)     430 (54.7)     
      ex-smokers                     58 (22.8)            125 (29.9)    295 (30.9)     268 (32.3)     
      current-smokers                84 (33.1)            97 (23.2)     171 (17.9)     133 (16.0)     
  **Alcohol consumption**                                                                             0.005
      no                             133 (53.4)           231 (56.6)    594 (63.0)     543 (62.9)     
      moderate (≤15 g/day)           66 (26.5)            115 (28.2)    222 (23.5)     210 (25.7)     
      high (\>15 g/day)              50 (20.1)            62 (15.2)     127 (13.5)     93 (11.4)      
  **Sedentary life**                 163 (64.2)           212 (50.8)    488 (51.2)     437 (52.5)     0.002
  **BMI**                                                                                             0.388
      \<25 kg/m^2^                   123 (50.6)           224 (54.9)    511 (55.8)     317 (50.2)     
      25--30 kg/m^2^                 82 (33.7)            127 (31.1)    295 (32.2)     292 (35.1)     
      \>30 kg/m^2^                   38 (14.7)            57 (14.0)     110 (12.0)     122 (14.7)     
  **Diabetes**                       9 (3.5)              11 (2.6)      35 (3.7)       31 (3.7)       0.766
  **Hypertension**                   80 (31.6)            91 (21.8)     243 (25.4)     199 (24.0)     0.032
  **Dyslipidaemia**                  97 (38.2)            115 (27.7)    277 (29.0)     254 (30.5)     0.022
  **FEV**~**1**~ (L)                 3.15 ± 0.87          3.24 ± 0.89   3.29 ± 0.83    3.32 ± 0.78    \<0.001
  **FVC** (L)                        4.02 ± 1.09          4.20 ± 1.15   4.05 ± 1.03    4.04 ± 0.96    \<0.001
  **FEV**~**1**~**/FVC ratio (%)**   78.6 ± 8.6           77.4 ± 6.8    81.3 ± 6.3     82.4 ± 6.0     \<0.001
  **FEV**~**1**~ (% of predicted)    96.2 ± 14.7          94.4 ± 14.0   100.9 ± 12.9   103.2 ± 12.3   \<0.001
  **Atopy**                          122 (57.8)           278 (79.0)    498 (62.5)     177 (26.0)     \<0.001

Data are presented as n (%) or mean ± standard deviation.

The groups differed in the distribution of sex and age, as well as of most of lifestyle variables and cardiovascular risk factors: education, smoking habits, alcohol consumption, physical activity, hypertension, dyslipidaemia ([Table 2](#pone.0224999.t002){ref-type="table"}). In particular, CB was significantly associated with female sex (RRR 1.63, 95%CI: 1.31--2.04), younger age (0.96, 0.94--0.98), and low education (1.78; 1.24--2.54) ([Table 3](#pone.0224999.t003){ref-type="table"}).

10.1371/journal.pone.0224999.t003

###### Relative risk ratios, with 95% confidence intervals, for the associations of demographics, cardiovascular risk factors and comorbidities with CB, asthma, and rhinitis.

![](pone.0224999.t003){#pone.0224999.t003g}

  -------------------------------------------------------------------------------------------------------
                                  Chronic bronchitis\     Asthma\                 Rhinitis\
                                  vs. Controls\           vs. Controls\           vs. Controls\
                                  RRR (95% CI)            RRR (95% CI)            RRR (95% CI)
  ------------------------------- ----------------------- ----------------------- -----------------------
  **Sex** (female vs. male)       **1.63 (1.31--2.04)**   0.91 (0.76--1.10)       1.09 (0.96--1.24)

  **Age** (per year increase)     **0.96 (0.94--0.98)**   **0.96 (0.95--0.98)**   0.99 (0.98--1.00)

  **Education** (low vs. high)    **1.78 (1.24--2.54)**   1.00 (0.66--1.50)       0.82 (0.66--1.02)

  **Smoking habits**                                                              

      ex vs. never smokers        0.78 (0.59--1.03)       1.15 (0.91--1.46)       1.01 (0.84--1.22)

      current vs. never smokers   **2.00 (1.41--2.84)**   **1.52 (1.20--1.94)**   1.16 (0.98--1.37)

  **Alcohol consumption**                                                         

      moderate vs. no             1.27 (0.87--1.86)       0.98 (0.74--1.28)       0.90 (0.70--1.16)

      high vs. no                 **2.55 (1.61--4.03)**   1.44 (0.99--2.11)       1.22 (0.92--1.61)

  **Sedentary vs. active life**   **1.59 (1.05--2.42)**   1.02 (0.83--1.26)       0.96 (0.73--1.26)

  **BMI**                                                                         

  25--30 vs. \<25 kg/m^2^         1.00 (0.78--1.30)       0.91 (0.66--1.27)       **0.86 (0.79--0.94)**

  \>30 vs \<25 kg/m^2^            0.88 (0.64--1.21)       0.99 (0.75--1.30)       0.73 (0.52--1.03)

  **Diabetes** (yes vs.no)        0.91 (0.50--1.67)       0.82 (0.38--1.79)       1.12 (0.78--1.61)

  **Hypertension** (yes vs.no)    **1.90 (1.14--3.15)**   **1.41 (1.06--1.89)**   **1.42 (1.13--1.77)**

  **Dyslipidaemia** (yes vs.no)   **1.66 (1.19--2.31)**   1.02 (0.84--1.24)       0.95 (0.83--1.09)
  -------------------------------------------------------------------------------------------------------

Adjusted for all the variables included in the table. RRR, relative risk ratio

Current smoking (2.00, 1.41--2.84), high alcohol consumption (2.55, 1.61--4.03) and sedentary life (1.59, 1.05--2.42) were also associated with an increased risk of CB. The risk of having asthma was higher in younger subjects (0.96, 0.95--0.98) and in current smokers (1.52, 1.20--1.94). The risk of having rhinitis was lower in overweight subjects (0.86, 0.79--0.94). Hypertension was significantly associated with CB (1.90, 1.14--3.15), asthma (1.41, 1.06--1.89) and rhinitis (1.42, 1.13--1.77). Dyslipidaemia was associated with CB (1.66, 1.19--2.31).

The crude prevalence of heart disorders was higher among cases of CB and rhinitis (14.2% and 12.1%) compared to controls and asthma cases (10.1% and 9.3%) ([Fig 1](#pone.0224999.g001){ref-type="fig"}).

![Prevalence of heart disorders and intermittent claudication in subjects with CB, asthma, rhinitis, and controls.](pone.0224999.g001){#pone.0224999.g001}

After adjustment for all cardiovascular risk factors and comorbidities ([Fig 2](#pone.0224999.g002){ref-type="fig"}, model 3), heart disorders were significantly associated with CB (RRR, 95%CI: 1.58, 1.12--2.22; p = 0.009). A borderline association was also detected between heart disorders and rhinitis (RRR, 95%CI: 1.35, 0.98--1.85; p = 0.066).

![Relative risk ratios (RRR) with 95% CIs for the associations of CB, asthma, and rhinitis with heart disorders and intermittent claudication.\
Model 1 (white triangles): adjusted for age and gender; model 2 (grey triangles): adjusted for age, gender, school education, smoking status, alcohol consumption, BMI, physical activity; model 3 (black triangles): adjusted for variables in model 2 plus diabetes, hypertension, dyslipidaemia.](pone.0224999.g002){#pone.0224999.g002}

The prevalence of intermittent claudication was higher in all the cases groups (10.6%, 4.8%, 6.0% in CB, asthma, and rhinitis groups, respectively) than in controls (3.3%) ([Fig 1](#pone.0224999.g001){ref-type="fig"}). In the fully adjusted model ([Fig 2](#pone.0224999.g002){ref-type="fig"}, model 3), intermittent claudication was significantly associated with a 3.5-fold higher risk of CB (RRR 3.43, 95%CI: 2.52--4.67; p\<0.001), a 2-fold higher risk of rhinitis (2.03, 1.34--3.07; p\<0.001), and a 1.5-fold higher risk of asthma (1.51, 1.04-2-21; p = 0.032).The associations were confirmed when using different sets of adjustment variables ([Fig 2](#pone.0224999.g002){ref-type="fig"}, models 1 and 2).

Discussion {#sec014}
==========

In the present analysis of data from the general population, we found that heart disorders and intermittent claudication, an indicator of symptomatic peripheral artery disease, were both strongly associated with CB and, to a minor extent, with rhinitis; intermittent claudication was also associated with asthma. Our data also indicate that cardiovascular risk factors are frequently associated with respiratory illnesses. Particularly, our findings support that unhealthy lifestyles (smoking, high alcohol consumption and sedentariness), hypertension and dyslipidaemia may predict a greater risk of CB.

Our findings should be interpreted keeping in mind that, in this multicase-control study, we used a hierarchical classification of diseases, so that cases of chronic bronchitis may also suffer from asthma and rhinitis, and cases of asthma could also be affected by rhinitis. Furthermore we underline that control subjects were accurately selected on the basis of the absence of CB, asthma and rhinitis.

CB was strongly and independently associated with heart disorders. Of note, as cases of COPD were excluded from the analysis, all subjects reporting CB presented a preserved lung function. Our results are in agreement with previous studies, demonstrating an increased risk of coronary disease and mortality among subjects with symptoms of CB \[[@pone.0224999.ref004],[@pone.0224999.ref027],[@pone.0224999.ref028]\]. In the above mentioned studies, lung function test was not performed, so that CB population could include subjects with COPD, which is known to be associated with cardiovascular diseases \[[@pone.0224999.ref002]\]. Lange et al. \[[@pone.0224999.ref005]\] and Guerra et al.\[[@pone.0224999.ref003]\] demonstrated an association between CB without bronchial obstruction, and all-cause death, indirectly supporting the results from the present analysis.

This study is the first to report an association between CB and intermittent claudication, which remained significant after controlling for all the most important cardiovascular risk factors. These results suggest that CB may be an independent risk factor for atherosclerosis.

The lack of a significant association between asthma and heart disorders is in agreement with Schanen and colleagues, who reported that asthma is not a risk factor for coronary heart disease \[[@pone.0224999.ref010]\]. Nonetheless, some reports suggested an association of asthma with carotid atherosclerosis, coronary heart disease and stroke \[[@pone.0224999.ref009]--[@pone.0224999.ref014]\]. One possible explanation for the contrasting results is the fact that, differently from previous studies \[[@pone.0224999.ref009]--[@pone.0224999.ref012]\], we analysed asthma separately from CB, a disorder we found strongly associated with cardiovascular risk factors and diseases. Furthermore, in our study asthma was precisely characterized, whereas it was self-reported in some previous investigations \[[@pone.0224999.ref013]\], a fact that could introduce a bias of misclassification with COPD \[[@pone.0224999.ref029]\].

Extending the finding of our previous analysis that was carried out using data from the centre of Verona alone \[[@pone.0224999.ref016]\], subjects with rhinitis and/or asthma had an increased risk of suffering from intermittent claudication.

Few studies investigated the relationship between cardiovascular diseases and rhinitis \[[@pone.0224999.ref017],[@pone.0224999.ref030]\]. In disagreement with our results, Hirsch et al. did not find a significant association between chronic rhino-sinusitis and post-morbid cardiovascular conditions \[[@pone.0224999.ref031]\].

The strong association of smoking with CB is not surprising \[[@pone.0224999.ref032]\], but we also found an increased risk of asthma among current smokers, in line with findings from others \[[@pone.0224999.ref033],[@pone.0224999.ref034]\].

Our results do not support previous findings suggesting a relationship between smoking and prevalence of chronic rhinitis \[[@pone.0224999.ref035]\].

We found an association between dyslipidaemia and CB. Subjects with CB are more likely to be heavy smokers and alcohol consumers, which may be responsible of an altered lipid metabolism \[[@pone.0224999.ref036],[@pone.0224999.ref037]\]. However, the association between dyslipidaemia and CB persisted after controlling for these confounders.

Another interesting result is that subjects with rhinitis were less likely to be overweight or obese, which was also observed in other two recent surveys \[[@pone.0224999.ref038],[@pone.0224999.ref039]\].

Differently from previous studies showing an association between obesity and the risk of asthma \[[@pone.0224999.ref040]\], we found no relationship between asthma and BMI.

In agreement with previous studies \[[@pone.0224999.ref041]\], elevate alcohol consumption was independently correlated with CB. Alcohol acts systemically with various mechanisms (alteration of immunity and promotion of systemic inflammation) \[[@pone.0224999.ref042]\], that may be involved in both the respiratory and cardiovascular damage.

Our finding of a relationship between rhinitis and hypertension is consistent with a previous study by Kony et al. \[[@pone.0224999.ref043]\]. Our data also indirectly support another case-control study that suggested an increased incidence of hypertension among subjects with rhino-sinusitis \[[@pone.0224999.ref031]\]. While the association between COPD and hypertension has widely been described \[[@pone.0224999.ref002]\], our study is the first to report a strong positive association between CB and this risk factor. Our data also show the increased risk of arterial hypertension among asthmatic subjects, in agreement with previous findings from large population based studies \[[@pone.0224999.ref009],[@pone.0224999.ref044]\].

The nature of the association of cardiovascular disorders with rhinitis and CB remains speculative and several mechanisms, such as infection \[[@pone.0224999.ref045]--[@pone.0224999.ref047]\] and inflammation, may play a role. The association of atherosclerosis with respiratory diseases could also be caused by the inherent susceptibility of some subjects to specific inflammatory pathways. There is evidence that patients with rhino-sinusitis \[[@pone.0224999.ref048]\] and CB \[[@pone.0224999.ref003]\] have higher levels of C-reactive protein, a predictive marker of coronary heart disease \[[@pone.0224999.ref049]\].

Asthma and CB are both characterized by chronic inflammation in the lung, even though the nature of the inflammation differs between the two disorders \[[@pone.0224999.ref008],[@pone.0224999.ref050]\]. The different types of inflammation probably result in distinct pathology, clinical manifestation \[[@pone.0224999.ref008]\], and could differently influence the development of cardiovascular comorbidities.

Finally, reversal causation could not be excluded, since our study design does not consent to assess the temporal relationship between respiratory disorders, cardiovascular diseases and risk factors. Subjects affected by cardiovascular disease and hypertension often use medication that might induce respiratory symptoms (such as cough) or disorders (such as rhinitis) \[[@pone.0224999.ref051]\]. However the association between rhinitis, CB, asthma and hypertension was not modified after adjusting for antihypertensive treatment (data not shown).

The strength of our analysis is based on the standardized protocol which allowed a precise definition of each respiratory disease. A limit is that cardiovascular events were self-reported. However, a previous study from the general population showed a good sensitivity and specificity for self-reported diagnosis of cardiovascular events \[[@pone.0224999.ref024]\].

We conclude that a better understanding of the relationship between respiratory and cardiovascular diseases could have important clinical implications. First of all, CB, which is often considered as a minor symptom, has to be viewed as a status possibly evolving not only to irreversible airway obstruction \[[@pone.0224999.ref003]\] but also to cardiovascular damage. Secondly, there are possible consequences for disease management, such as screening, prevention and early treatment of cardiovascular diseases and risk factors in patients with chronic bronchitis, even in absence of irreversible airflow obstruction. In turn, in patients with cardiovascular diseases caution should be adopted about the use of drugs that could negatively interfere with the respiratory system (e.g. angiotensin-converting enzyme inhibitors potentially inducing cough).

In our study, cases of CB may also suffer from asthma and rhinitis. Thus our data suggest the crucial weight of cough and phlegm in driving the association between respiratory and cardiovascular risk factors and diseases. As a matter of fact, the strength of the associations was lower among subjects with asthma or rhinitis who did not complain of CB. This attention to CB may have also a strong preventive consequence, since the disease is generally present even without a clinically significant airway derangement. A similar consideration is also of importance for rhinitis, taking into account its association with peripheral arterial disease.

Finally, although the design of our study does not allow definitive conclusions, we are tempted to speculate that some cardiovascular risk factors, such as sedentariness, hypertension and dyslipidaemia, might also be involved in the development of respiratory diseases.

Supporting information {#sec015}
======================

###### Minimal anonymised data set to replicate the analyses.

(CSV)

###### 

Click here for additional data file.

BMI

:   body mass index

CB

:   chronic bronchitis

COPD

:   chronic obstructive pulmonary disease

FEV~1~

:   forced expiratory volume in 1 second

FVC

:   forced vital capacity

GEIRD

:   Gene Environment Interactions in Respiratory Diseases

LLN

:   lower limit of normal

PD~20~

:   provocative dose causing a 20% decrease in FEV~1~

RRR

:   relative risk ratios
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To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Davor Plavec

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

1\. Thank you for inlcuding your ethics statement; \"Ethical approval was obtained in each centre from the appropriate ethics committee, and written consent was obtained from each participant (see Acknowledgements).\"

Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to <http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research>

2\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Additional Editor Comments (if provided):

Please submit the revised manuscript according to the suggestions of reviewer.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: My major concern is a definition of the groups. For CB from the text I understand that their lung function was normal. That should be stated in the definition. Also since they were tested to allergies and metacholine was that an exclusion criteria? If yes that should be stated in the definition and an explanation of what caused CB since they were younger and 44% non-smokers? Asthma group shouldn't be defined by 1. Criteria, only the second criteria is excluding non asthmatics from the group. Where are asthma and CB patients with rhinitis? Are they in asthma and CB groups (should be stated how much) or excluded?

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Journal Requirements

1\) Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

We have revised the style of the manuscript to fulfil PLOS ONE requirements, including title page requirements, labelling of Figures, file naming, and reference formatting.

2\) Thank you for including your ethics statement; \"Ethical approval was obtained in each centre from the appropriate ethics committee, and written consent was obtained from each participant (see Acknowledgements).\" Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study. Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

We have implemented this change in the manuscript (lines 106-112 of the tracked-changes version) and amended the ethics statement in the online submission form.

3\) We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

We have included a "minimal anonymised data set" as an additional online supplementary file (S1 Dataset), and updated our data availability statement accordingly.

4\) While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

We have checked the figure files using PACE as requested.

Reviewers\' comments

1\) My major concern is a definition of the groups. For CB from the text I understand that their lung function was normal. That should be stated in the definition.

Thanks for your comment. We have revised the definition of chronic bronchitis as suggested (line 132 in the tracked-changes version of the manuscript).

2\) Also since they were tested to allergies and metacholine was that an exclusion criteria? If yes that should be stated in the definition and an explanation of what caused CB since they were younger and 44% non-smokers?

As reported in the Methods section, we adopted a hierarchical classification of cases (lines 259-261). As a consequence, chronic bronchitis has cough and phlegm without bronchial obstruction as a hallmark, but in this group also subjects with asthma, rhinitis or atopy may be present. Positive skin prick tests or positive methacholine challenge were not exclusion criteria.

In the group of subjects with chronic bronchitis, the symptoms may be related to causes other than smoking, including e.g. post-nasal drip and airway inflammation of asthma. Moreover, we cannot rule out that the symptoms can be linked to air pollution, which is a major issue in the Po Valley (Verona, Pavia and Turin centres). As highlighted in the manuscript, our findings suggest the critical clinical relevance of cough and phlegm even in the absence of smoking.

3\) Asthma group shouldn't be defined by 1. Criteria, only the second criteria is excluding non asthmatics from the group.

"Definition 1" is "self-reported asthma, plus one among having had an asthma attack in the last 12 months or current use of medications for asthma". This epidemiological disease definition has been widely used, and validated in studies demonstrating an excellent specificity, 99.7% (de Marco R et al. Eur Respir J. 1998;11: 599-605).

4\) Where are asthma and CB patients with rhinitis? Are they in asthma and CB groups (should be stated how much) or excluded?

Due to our hierarchical definitions, subjects with rhinitis could be included either among cases of chronic bronchitis, or among cases of asthma, or among cases of rhinitis alone. This is explained in lines 131-140 of the manuscript.

In the revised manuscript, we have added the following sentence to the results section (lines 192-194): "As a result of our hierarchical definitions, cases of chronic bronchitis could also be affected by asthma (n=115, 45.3%) as well as rhinitis (n=205, 80.7%), and cases of asthma could also be affected by rhinitis (n=354, 84.7%)".

We thank the reviewer for the time he/she dedicated in reviewing the manuscript.
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Dear Dr. Alessandro Marcon,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Davor Plavec

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

After suggested revision the manuscript is acceptable for publication in its current form.

Reviewers\' comments:
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Chronic bronchitis without airflow obstruction, asthma and rhinitis are differently associated with cardiovascular risk factors and diseases

Dear Dr. Marcon:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Davor Plavec

Academic Editor

PLOS ONE
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